Advances in the treatment of neuroendocrine tumors

Area of Science:

• Oncology
• Gastroenterology
• Endocrinology

Background:

• Gastrointestinal neuroendocrine tumors (GI-NETs) exhibit slow growth and hormone secretion.
• Localized GI-NETs are often curable with surgery, but metastatic disease poses treatment challenges.
• Current treatments like somatostatin analogs manage symptoms but rarely induce tumor regression.

Purpose of the Study:

• To review current therapeutic strategies for GI-NETs.
• To explore novel treatment avenues, including angiogenesis inhibition and tyrosine kinase inhibitors.
• To highlight the challenges in evaluating treatment efficacy for indolent tumors.

Main Methods:

• Literature review of existing GI-NET treatment modalities.
• Discussion of emerging therapies and their mechanisms of action.
• Analysis of challenges in clinical trial design for slow-growing tumors.

Main Results:

• Somatostatin analogs effectively control hormonal symptoms but not tumor regression.
• Surgical debulking, embolization, and ablative therapies may benefit selected patients with hepatic metastases.
• Systemic agents like interferon and chemotherapy have limited efficacy and potential toxicity.
• Angiogenesis inhibitors and tyrosine kinase inhibitors are under investigation for novel treatment strategies.

Conclusions:

• Metastatic GI-NETs require diverse therapeutic approaches beyond symptom management.
• Novel agents targeting angiogenesis and tyrosine kinases represent promising avenues.
• Larger, randomized trials and validated surrogate endpoints are crucial for assessing new treatments for GI-NETs.